Does Ocular's Latest CRL Mean A Minor Delay For Dextenza, Or A New NDA?
Executive Summary
The biotech sought a three-month action date extension with new manufacturing process data submitted to FDA just one day before the complete response letter.
You may also be interested in...
Ocular Analyzes Particulates Root Cause After Whiffing With Steel Blade
Ocular takes another swing at resolving the manufacturing issues that resulted in a complete response letter for its Dextenza.
Keeping Track: Tremfya Clears FDA; Dextenza Amendment Is Too Late; Emicizumab, Abemaciclib Filed
The latest drug development news and highlights from our US FDA Performance Tracker.
Ocular Therapeutix Gets Lead Product Back On Track
The long-acting eye insert Dextenza has been accepted for review by the US FDA, a piece of good news for Ocular Therapeutix that had previously received a complete response letter on manufacturing issues and a mixed bag of late-stage clinical trial results.